Compare Cipla with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs STRIDES PHARMA SCIENCE - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA STRIDES PHARMA SCIENCE CIPLA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 24.5 15.8 155.4% View Chart
P/BV x 2.5 0.9 268.6% View Chart
Dividend Yield % 0.6 0.5 123.1%  

Financials

 CIPLA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    CIPLA
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
CIPLA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs6781,147 59.1%   
Low Rs484642 75.4%   
Sales per share (Unadj.) Rs198.2317.2 62.5%  
Earnings per share (Unadj.) Rs18.57.8 236.1%  
Cash flow per share (Unadj.) Rs35.025.1 139.6%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %0.50.2 231.0%  
Book value per share (Unadj.) Rs186.3274.3 67.9%  
Shares outstanding (eoy) m805.7089.50 900.2%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.92.8 103.9%   
Avg P/E ratio x31.4114.0 27.5%  
P/CF ratio (eoy) x16.635.7 46.5%  
Price / Book Value ratio x3.13.3 95.6%  
Dividend payout %16.225.5 63.5%   
Avg Mkt Cap Rs m468,03180,058 584.6%   
No. of employees `00022.62.5 903.2%   
Total wages/salary Rs m28,5654,341 658.1%   
Avg. sales/employee Rs Th7,053.111,325.8 62.3%   
Avg. wages/employee Rs Th1,261.51,731.4 72.9%   
Avg. net profit/employee Rs Th659.1280.1 235.3%   
INCOME DATA
Net Sales Rs m159,71028,394 562.5%  
Other income Rs m4,766941 506.7%   
Total revenues Rs m164,47529,334 560.7%   
Gross profit Rs m30,9733,965 781.1%  
Depreciation Rs m13,2631,540 861.0%   
Interest Rs m1,6841,962 85.8%   
Profit before tax Rs m20,7911,403 1,481.7%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m5,69597 5,853.3%   
Profit after tax Rs m14,924702 2,125.7%  
Gross profit margin %19.414.0 138.9%  
Effective tax rate %27.46.9 395.0%   
Net profit margin %9.32.5 377.9%  
BALANCE SHEET DATA
Current assets Rs m124,26624,836 500.3%   
Current liabilities Rs m37,71518,993 198.6%   
Net working cap to sales %54.220.6 263.4%  
Current ratio x3.31.3 252.0%  
Inventory Days Days9171 127.7%  
Debtors Days Days95113 83.6%  
Net fixed assets Rs m105,19034,289 306.8%   
Share capital Rs m1,611895 180.0%   
"Free" reserves Rs m148,51123,651 627.9%   
Net worth Rs m150,12324,546 611.6%   
Long term debt Rs m38,30115,513 246.9%   
Total assets Rs m239,63365,437 366.2%  
Interest coverage x13.31.7 778.1%   
Debt to equity ratio x0.30.6 40.4%  
Sales to assets ratio x0.70.4 153.6%   
Return on assets %6.94.1 170.2%  
Return on equity %9.92.9 347.6%  
Return on capital %11.86.9 171.7%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41015,697 365.7%   
Fx outflow Rs m19,041735 2,589.2%   
Net fx Rs m38,36814,962 256.4%   
CASH FLOW
From Operations Rs m16,9111,871 904.0%  
From Investments Rs m-16,6875,826 -286.4%  
From Financial Activity Rs m-3,487-10,157 34.3%  
Net Cashflow Rs m-3,451-2,615 132.0%  

Share Holding

Indian Promoters % 16.0 27.7 57.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 37.8 32.3%  
FIIs % 23.7 8.6 275.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 25.9 101.2%  
Shareholders   161,166 56,241 286.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

WPI Inflation Data, Global Stock Market Drivers, and Top Cues in Focus Today(Pre-Open)

On Monday, Indian share markets witnessed negative trading activity throughout the day and ended lower.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 17, 2019 09:39 AM

TRACK CIPLA

CIPLA - SANOFI INDIA COMPARISON

COMPARE CIPLA WITH

MARKET STATS